David Shriner, MD
Dermatology · San Antonio, TXNPI 1609884915
Payments from drug & device makers
Across 90 payments — averaging $19.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$957
- Lilly USA, LLC$189
- Sun Pharmaceutical Industries Inc.$68
- Incyte Corporation$56
- Dermavant Sciences, Inc.$54
- Journey Medical Corporation$47
- plus $414 from 16 others
What the payments were for
- Food & beverage$1,786100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 47 | $957 |
| Lilly USA, LLC | 9 | $189 |
| Sun Pharmaceutical Industries Inc. | 3 | $68 |
| Incyte Corporation | 3 | $56 |
| Dermavant Sciences, Inc. | 3 | $54 |
| Journey Medical Corporation | 2 | $47 |
| Boehringer Ingelheim | 2 | $44 |
| UCB, Inc. | 2 | $40 |
| Biofrontera Inc. | 3 | $38 |
| Nabriva Therapeutics, PLC | 2 | $37 |
| LEO Pharma Inc. | 3 | $36 |
| Fresenius Kabi USA, LLC | 1 | $30 |
| Revance Therapeutics, Inc. | 1 | $27 |
| Novartis | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Sanofi | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Convatec Inc. | 1 | $19 |
| Mayne Pharma Commercial LLC | 1 | $19 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $15 |
| Aclaris Therapeutics, Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $11 |
How this compares
$1,786 in reported general payments places this provider in the 30th percentile of 1,098 dermatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Doxycycline Hyclate | 65 | $624 |
Paid to pharmacies, not to this prescriber.
Other dermatology in San Antonio
- Mark LeeSan Antonio$10.9M
- John BrowningSan Antonio$10.7M
- Emily BeckerSan Antonio$2.4M
- William CragunSan Antonio$2.3M
- Steven DavisSan Antonio$1.8M
- Lindsey FinkleaSan Antonio$1.2M
- Stephen MillerSan Antonio$389K
- Vivian BucaySan Antonio$241K
- Stephen TyringWebster$14.1M
- Edward LainAustin$12M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.